Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Effekt av högflödesterapi i långvarig syreterapi (HILOT)

16 november 2026 uppdaterad av: Magnus Ekström, Skane University Hospital

Effekt av högflödesterapi i långtidsbehandling med syre (HILOT): En multicenter, registerbaserad, randomiserad klinisk prövning

This is a registry-based, randomized, controlled clinical trial of the effect of added high-flow oxygen therapy (using the device Lumis HFT) during one year in people with long-term oxygen therapy (LTOT) for chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD).

Studieöversikt

Detaljerad beskrivning

This is a registry-based, randomized, controlled clinical trial of patients with LTOT for COPD or ILD recruited using the Swedish National Registry for Respiratory Failure (Swedevox) in collaboration with a research network within the Swedish Respiratory Society. The trial evaluates the effect of added high-flow oxygen therapy nighttime to the regular low-flow oxygen therapy compared with regular low-flow oxygen therapy alone up to one year.

The purpose of this project is to improve evidence-based treatment of people with chronic respiratory failure, currently about 2000 patients annually in Sweden, who have high risk of adverse events and mortality.

Studietyp

Interventionell

Inskrivning (Beräknad)

310

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

      • Örebro, Sverige, 70185
        • Rekrytering
        • Department of Heart, Lung and Clinical Physiology, Örebro University Hospital
        • Kontakt:
          • Josefin Sundh, MD, PhD
    • Blekinge County
      • Karlskrona, Blekinge County, Sverige, 37185
        • Rekrytering
        • Research Unit, Blekinge University of Technology
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Age 40 years or older
  • Ongoing LTOT: prescribed for at least 15 hours per day; and since at least 28 days as registered in Swedevox
  • COPD or ILD as main underlying reason for LTOT
  • Oxygen concentrator as stationary oxygen source in the home including night-time
  • Body mass index (BMI) < 35 kg/m2

Exclusion Criteria:

  • Current or previous treatment with home HFOT
  • Current treatment with home mechanical ventilation
  • Current treatment with home CPAP
  • Hospitalized during the last 2 weeks
  • Current smoking or contact with flames
  • Self-reported average use of the LTOT < 15h per day (24 hours)
  • PaCO2 (breathing air at rest) > 8 kPa
  • Strong clinical suspicion of obstructive sleep apnea (OSA) or obesity-related hypoventilation syndrome (OHS) (as judged by the responsible staff)
  • Inability to participate in the study procedures (as judged by the staff)
  • Not eligible for continuing LTOT due to other reason (as judged by the staff)
  • Expected survival less than 3 months (as judged by the staff)

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: High-flow oxygen therapy

Intervention arm

Added high-flow oxygen therapy using the device Lumis HFT during nighttime and at the patient's discretion daytime, with the usual care (low-flow oxygen therapy) the rest of the time.

Aktiv komparator: Low-flow oxygen therapy

Comparison arm

Standard care with low-flow oxygen therapy in accordance with clinical routine.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Time to first hospitalization or death from all causes
Tidsram: 1 year

Time to first hospitalization or death from all causes during 1 year after randomization in people with COPD (assessed using nationwide registry data)

1 year

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Time to first all-cause hospitalization or all-cause death
Tidsram: 1 year

Time to first all-cause hospitalization or all-cause death in people with ILD (assessed using nationwide registry data)

1 year
Rate of hospitalizations or death from all causes
Tidsram: 1 year

Rate of hospitalizations or death from all causes assessed using nationwide registry data

1 year
Hospitalization rate from all causes
Tidsram: 1 year

Hospitalization rate from all causes assessed using nationwide registry data

1 year
Hospitalization rate from respiratory disease
Tidsram: 1 year

Hospitalization rate from respiratory disease assessed using nationwide registry data

1 year
Number of hospitalized days
Tidsram: 1 year

Number of hospitalized days from all-causes, respiratory and cardiovascular disease using nationwide registry data

1 year
Hospitalization rate from cardiovascular disease
Tidsram: 1 year

Hospitalization rate from cardiovascular disease assessed using nationwide registry data

1 year
Number of admissions to intensive care unit (ICU)
Tidsram: 1 year

Number of admissions to ICU assessed using nationwide registry data

1 year
Number of days in ICU
Tidsram: 1 year

Number of days in ICU assessed using nationwide registry data

1 year
Mortality rate from all causes
Tidsram: 1 year

The mortality rate from all causes assessed using nationwide registry data

1 year
Mortality rate from respiratory disease
Tidsram: 1 year

The mortality rate from respiratory disease assessed using nationwide registry data

1 year
Mortality rate from cardiovascular disease
Tidsram: 1 year

The mortality rate from cardiovascular disease assessed using nationwide registry data

1 year
Time to first exacerbation
Tidsram: 1 year

Time to first exacerbation after randomisation, defined as time to first dispensed antibiotics and/or oral corticosteroids, ED-visit or hospitalization for exacerbation assessed using self-reported and registry data

1 year
Number of exacerbations
Tidsram: 1 year

Number of exacerbations of all severity assessed using self-reported and registry data

1 year
Incidence of cardiovascular disease
Tidsram: 1 year

Incidence of cardiovascular disease assessed using nationwide registry data

1 year
Need for home mechanical ventilation
Tidsram: 1 year

Need for starting home mechanical ventilation assessed using nationwide registry data

1 year
Rate of withdrawal of long-term oxygen therapy
Tidsram: 1 year

Rate of withdrawal of long-term oxygen therapy assessed using nationwide registry data

1 year
Adverse events
Tidsram: 3 and 12 months

Self-reported adverse events since study start assessed using a postal questionnaire.

3 and 12 months
Primary care utilization
Tidsram: 1 year

Self-reported number of primary care contacts since the start of the study assessed using a postal questionnaire.

1 year
Health-related quality of life
Tidsram: 3 and 12 months

Self-reported health-related quality of life assessed using the EuroQol Five Dimensions - Five Levels (EQ5D-5L) questionnaire.

3 and 12 months
Health status
Tidsram: 3 and 12 months

Self-reported health status assessed using the and the COPD Assessment Test (CAT) questionnaire.

3 and 12 months
Breathlessness at exertion
Tidsram: 3 and 12 months

Self-reported exertional breathlessness assessed using the Dyspnoea Exertion Scale (DES) questionnaire.

3 and 12 months
Breathlessness
Tidsram: 3 and 12 months

Self-reported breathlessness assessed using the Dyspnea-12 questionnaire.

3 and 12 months
Sleep quality
Tidsram: 3 and 12 months

Self-reported sleep quality assessed using the modified Basic Nordic Sleep Questionnaire.

3 and 12 months
Physical activity
Tidsram: 3 and 12 months

Self-reported level of physical activity assessed using the modified Grimby-Frändin questionnaire.

3 and 12 months
Change in health status
Tidsram: 3 and 12 months

Self-reported change in perceived health status assessed using the Global Impression of Change (GIC) scale.

3 and 12 months
Nasal symptoms
Tidsram: 3 and 12 months

Self-reported nasal symptoms assessed using the modified Björklund questionnaire.

3 and 12 months

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Patient preference for continuing the treatment
Tidsram: 3 and 12 months

Patients' self-reported patient preference for continuing the treatment assessed using postal questionnaire.

3 and 12 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

10 juni 2024

Primärt slutförande (Beräknad)

1 december 2028

Avslutad studie (Beräknad)

1 december 2029

Studieregistreringsdatum

Först inskickad

17 januari 2024

Först inskickad som uppfyllde QC-kriterierna

6 februari 2024

Första postat (Faktisk)

7 februari 2024

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

19 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

16 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

IPD-planbeskrivning

IPD cannot be shared due to restrictions in the current ethical approval. Pseudonymized IPD can be shared upon reasonable request and separate ethical approval.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera